| Intervention | Comparator | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Placebo + MTX | aTNF | TOF 5mg | TCZ | ABT + MTX | ANA + MTX | aTNF + MTX | TOF 5mg + MTX | TCZ + MTX | ||
| Placebo | OR (95% CrI) |
1.00 (1, 1) |
0.31 (0.03, 2.66) |
0.07 (0.01, 0.24) |
0.27 (0.05, 1.22) |
0.03 (0.00, 0.16) |
0.06 (0.00, 0.58) |
0.09 (0.01, 1.17) |
0.06 (0.00, 0.47) |
0.03 (0.00, 0.34) |
0.03 (0.00, 0.23) |
| P(better) | NA | 0.11 | < 0.01 | 0.04 | < 0.01 | 0.01 | 0.03 | 0.01 | < 0.01 | < 0.01 | |
| Placebo + MTX | OR (95% CrI) |
3.26 (0.38, 39.62) |
1.00 (1, 1) |
0.23 (0.04, 1.38) |
0.88 (0.06, 15.52) |
0.11 (0.02, 0.42) |
0.21 (0.11, 0.37) |
0.30 (0.07, 1.22) |
0.18 (0.11, 0.26) |
0.11 (0.05, 0.24) |
0.11 (0.04, 0.27) |
| P(better) | 0.89 | NA | 0.05 | 0.46 | < 0.01 | < 0.01 | 0.04 | 0.04 | < 0.01 | < 0.01 | |
| aTNF | OR (95% CrI) |
14.00 (4.23, 75.38) |
4.26 (0.73, 26.83) |
1.00 (1, 1) |
3.79 (0.50, 35.41) |
0.45 (0.15, 1.39) |
0.89 (0.13, 5.90) |
1.29 (0.13, 13.11) |
0.78 (0.12, 4.82) |
0.45 (0.07, 3.57) |
0.47 (0.10, 2.29) |
| P(better) | > 0.99 | 0.95 | NA | 0.90 | 0.06 | 0.44 | 0.60 | 0.37 | 0.18 | 0.13 | |
| TOF 5 mg | OR (95% CrI) |
3.76 (0.82, 20.18) |
1.14 (0.06, 17.29) |
0.26 (0.03, 2.01) |
1.00 (1, 1) |
0.12 (0.01, 1.19) |
0.24 (0.01, 3.70) |
0.34 (0.01, 7.36) |
0.21 (0.01, 3.08) |
0.12 (0.01, 2.15) |
0.12 (0.01, 1.61) |
| P(better) | 0.96 | 0.54 | 0.10 | NA | 0.03 | 0.13 | 0.23 | 0.11 | 0.06 | 0.05 | |
| TCZ | OR (95% CrI) |
31.19 (6.23, 242.41) |
9.42 (2.40, 40.26) |
2.22 (0.72, 6.82) |
8.36 (0.84, 103.30) |
1.00 (1,1) |
1.97 (0.43, 9.08) |
2.85 (0.40, 21.09) |
1.72 (0.40, 7.25) |
1.00 (0.22, 5.62) |
1.05 (0.37, 3.07) |
| P(better) | > 0.99 | > 0.99 | 0.94 | 0.97 | NA | 0.85 | 0.87 | 0.80 | 0.50 | 0.55 | |
| ABT + MTX | OR (95% CrI) |
15.69 (1.71, 208.60) |
4.80 (2.71, 9.34) |
1.12 (0.17, 7.50) |
4.19 (0.27, 83.54) |
0.51 (0.11, 2.31) |
1.00 (1, 1) |
1.46 (0.30, 6.86) |
0.88 (0.47, 1.59) |
0.51 (0.21, 1.47) |
0.54 (0.18, 1.60) |
| P(better) | 0.99 | > 0.99 | 0.56 | 0.87 | 0.15 | NA | 0.70 | 0.30 | 0.09 | 0.11 | |
| ANA + MTX | OR (95% CrI) |
11.17 (0.85,192.01) |
3.30 (0.82, 14.83) |
0.78 (0.08, 7.42) |
2.96 (0.14, 74.77) |
0.35 (0.05, 2.52) |
0.69 (0.15, 3.34) |
1.00 (1, 1) |
0.60 (0.13, 2.72) |
0.36 (0.07, 1.99) |
0.37 (0.07, 2.07) |
| P(better) | 0.97 | 0.96 | 0.40 | 0.77 | 0.13 | 0.30 | NA | 0.23 | 0.10 | 0.11 | |
| aTNF + MTX | OR (95% CrI) |
17.84 (2.13, 237.71) |
5.50 (3.80, 8.85) |
1.28 (0.21, 8.42) |
4.85 (0.32, 95.11) |
0.58 (0.14, 2.51) |
1.14 (0.63, 2.13) |
1.66 (0.37, 7.44) |
1.00 (1, 1) |
0.59 (0.28, 1.47) |
0.61 (0.23, 1.69) |
| P(better) | 0.99 | > 0.99 | 0.63 | 0.89 | 0.20 | 0.70 | 0.77 | NA | 0.11 | 0.15 | |
| TOF 5mg + MTX | OR (95% CrI) |
30.84 (2.95, 403.71) |
9.30 (4.10, 20.36) |
2.21 (0.28, 14.55) |
8.32 (0.47, 154.70) |
1.00 (0.18, 4.62) |
1.95 (0.68, 4.86) |
2.81 (0.50, 13.39) |
1.70 (0.68, 3.61) |
1.00 (1, 1) |
1.04 (0.29, 3.36) |
| P(better) | > 0.99 | > 0.99 | 0.82 | 0.94 | 0.50 | 0.91 | 0.90 | 0.89 | NA | 0.53 | |
| TCZ + MTX | OR (95% CrI) |
29.53 (4.35, 295.43) |
8.95 (3.72, 23.36) |
2.12 (0.44, 9.84) |
8.00 (0.62,122.50) |
0.95 (0.33, 2.72) |
1.86 (0.63, 5.61) |
2.72 (0.48, 15.04) |
1.63 (0.59, 4.40) |
0.96 (0.30, 3.50) |
1.00 (1, 1) |
| P(better) | > 0.99 | > 0.99 | 0.87 | 0.95 | 0.45 | 0.89 | 0.89 | 0.85 | 0.47 | NA | |
ABT = abatacept; ACR70 = 70% improvement in American College of Rheumatology criteria; ANA = anakinra; aTNF = anti-tumor necrosis factor; CrI = credible interval; mg = milligram; MTX = methotrexate; NA = not applicable; OR = odds ratio; P(better) = probability that treatment (in row) is showing greater response than comparator (in column); TCZ = tocilizumab; TOF = tofacitinib.